Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics

Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics

Radiolabeled gastrin-releasing peptide receptor (GRPR) antagonists have shown great promise for the theranostics of prostate cancer; however, their suboptimal metabolic stability leaves room for improvements. It was recently shown that the replacement of Gly<sup>11</sup> with Sar<sup&...

Full description

Bibliographic Details
Main Authors:	Ayman Abouzayed, Panagiotis Kanellopoulos, Alisa Gorislav, Vladimir Tolmachev, Theodosia Maina, Berthold A. Nock, Anna Orlova
Format:	Article
Language:	English
Published:	MDPI AG 2023-07-01
Series:	Biomolecules
Subjects:	prostate cancer GRPR antagonist theranostics PC-3 cells neprilysin
Online Access:	https://www.mdpi.com/2218-273X/13/7/1134

Similar Items

Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology
by: Panagiotis Kanellopoulos, et al.
Published: (2024-02-01)

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
by: Ayman Abouzayed, et al.
Published: (2019-07-01)

Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
by: Berthold A. Nock, et al.
Published: (2023-04-01)

Bioorthogonal Chemistry Approach for the Theranostics of GRPR-Expressing Cancers
by: Alice D’Onofrio, et al.
Published: (2022-11-01)

Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart
by: Maryam Oroujeni, et al.
Published: (2019-08-01)

Phase I Trial of [<sup>99m</sup>Tc]Tc-maSSS-PEG<sub>2</sub>-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors
by: Vladimir Chernov, et al.
Published: (2023-03-01)

NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [67Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice
by: Aikaterini Kaloudi, et al.
Published: (2017-11-01)

Optimizing the Profile of [<sup>99m</sup>Tc]Tc–NT(7–13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors
by: Panagiotis Kanellopoulos, et al.
Published: (2020-10-01)

The GRPR Antagonist [<sup>99m</sup>Tc]Tc-maSSS-PEG<sub>2</sub>-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity
by: Ayman Abouzayed, et al.
Published: (2023-05-01)

Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer
by: Ayman Abouzayed, et al.
Published: (2020-10-01)

The Effect of Mini-PEG-Based Spacer Length on Binding and Pharmacokinetic Properties of a 68Ga-Labeled NOTA-Conjugated Antagonistic Analog of Bombesin
by: Zohreh Varasteh, et al.
Published: (2014-07-01)

Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer
by: Bogdan Mitran, et al.
Published: (2019-09-01)

[<sup>111</sup>In]In/[<sup>177</sup>Lu]Lu-AAZTA<sup>5</sup>-LM4 SST<sub>2</sub>R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results
by: Berthold A. Nock, et al.
Published: (2023-02-01)

Toward Stability Enhancement of NTS<sub>1</sub>R-Targeted Radioligands: Structural Interventions on [<sup>99m</sup>Tc]Tc-DT1
by: Panagiotis Kanellopoulos, et al.
Published: (2023-08-01)

Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [<sup>68</sup>Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation
by: Fanny Lundmark, et al.
Published: (2023-01-01)

Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK<sub>2</sub>R Cancer Theranostic Agents: A Preclinical Study
by: Berthold A. Nock, et al.
Published: (2022-03-01)

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model
by: Fanny Lundmark, et al.
Published: (2020-07-01)

Preclinical assessment of IRDye800CW‐labeled gastrin‐releasing peptide receptor‐targeting peptide for near infrared‐II imaging of brain malignancies
by: Yuan Zhang, et al.
Published: (2023-07-01)

The effects of novel macrocyclic chelates on the targeting properties of the 68Ga-labeled Gastrin releasing peptide receptor antagonist RM2
by: Yinwen Wang, et al.
Published: (2023-06-01)

AM-37 and ST-36 Are Small Molecule Bombesin Receptor Antagonists
by: Terry W. Moody, et al.
Published: (2017-07-01)

Synaptic circuits involving gastrin-releasing peptide receptor-expressing neurons in the dorsal horn of the mouse spinal cord
by: Raphaëlle Quillet, et al.
Published: (2023-12-01)

Chemogenetic activation of central gastrin‐releasing peptide‐expressing neurons elicits itch‐related scratching behavior in male and female mice
by: Norikazu Kiguchi, et al.
Published: (2021-05-01)

Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands
by: Panagiotis Kanellopoulos, et al.
Published: (2020-06-01)

Effect of the versatile bifunctional chelator AAZTA5 on the radiometal labelling properties and the in vitro performance of a gastrin releasing peptide receptor antagonist
by: Michael Hofstetter, et al.
Published: (2020-11-01)

[<sup>99m</sup>Tc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models
by: Panagiotis Kanellopoulos, et al.
Published: (2020-07-01)

[<sup>68</sup>Ga]Ga-DATA<sup>5m</sup>-LM4, a PET Radiotracer in the Diagnosis of SST<sub>2</sub>R-Positive Tumors: Preclinical and First Clinical Results
by: Panagiotis Kanellopoulos, et al.
Published: (2022-11-01)

Gastrin-Releasing Peptide Receptor Mediates Activation of the Epidermal Growth Factor Receptor in Lung Cancer Cells
by: Sufi Mary Thomas, et al.
Published: (2005-04-01)

Imaging Properties and Tumor Targeting of <sup>68</sup>Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients
by: Leonhard Gruber, et al.
Published: (2022-11-01)

Towards Complete Tumor Resection: Novel Dual-Modality Probes for Improved Image-Guided Surgery of GRPR-Expressing Prostate Cancer
by: Maryana Handula, et al.
Published: (2022-01-01)

Preclinical Evaluation of <sup>99m</sup>Tc-Labeled GRPR Antagonists maSSS/SES-PEG<sub>2</sub>-RM26 for Imaging of Prostate Cancer
by: Ayman Abouzayed, et al.
Published: (2021-01-01)

Gastrin-releasing peptide receptor (GRPR) as a novel biomarker and therapeutic target in prostate cancer
by: Honghu Zhang, et al.
Published: (2024-12-01)

Nanostrategies for Therapeutic and Diagnostic Targeting of Gastrin-Releasing Peptide Receptor
by: Beata Paulina Rurarz, et al.
Published: (2023-02-01)

[<sup>99m</sup>Tc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: From Preclinical Evaluation to the First Clinical Outcomes
by: Berthold A. Nock, et al.
Published: (2021-10-01)

Localization of <sup>99m</sup>Tc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses
by: Aikaterini Kaloudi, et al.
Published: (2019-03-01)

Bis(Disulfide)-Bridged Somatostatin-14 Analogs and Their [<sup>111</sup>In]In-Radioligands: Synthesis and Preclinical Profile
by: Aikaterini Tatsi, et al.
Published: (2024-02-01)

Transdermal theranostics
by: Than, Aung, et al.
Published: (2021)

Two Novel [68Ga]Ga-Labeled Radiotracers Based on Metabolically Stable [Sar11]RM26 Antagonistic Peptide for Diagnostic Positron Emission Tomography Imaging of GRPR-Positive Prostate Cancer
by: Panagiotis Kanellopoulos, et al.
Published: (2024-04-01)

Radiolabeled Bombesin Analogs
by: Rosalba Mansi, et al.
Published: (2021-11-01)

Neprilysin Inhibitors and Bradykinin
by: Duncan J. Campbell, et al.
Published: (2018-09-01)

Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF
by: Suriya Prausmüller, et al.
Published: (2020-06-01)